Time to rethink extended thromboprophylaxis after cancer surgery?

Autor: Alsehly AA; Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia; Department of Medicine, The Ottawa Hospital Research Institute at University of Ottawa, Ottawa, Ontario, Canada., Wang TF; Department of Medicine, The Ottawa Hospital Research Institute at University of Ottawa, Ottawa, Ontario, Canada., Carrier M; Department of Medicine, The Ottawa Hospital Research Institute at University of Ottawa, Ottawa, Ontario, Canada. Electronic address: mcarrier@toh.ca.
Jazyk: angličtina
Zdroj: Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2023 Feb; Vol. 21 (2), pp. 198-199.
DOI: 10.1016/j.jtha.2022.11.015
Abstrakt: Competing Interests: Declaration of competing interests T.-F.W. reports research funding from Leo Pharma and advisory honoraria from Servier. M.C. reports grants from Bristol Myers Squibb, Leo Pharma, and Pfizer, personal fees from Bristol Myers Squibb, Leo Pharma, Bayer, Pfizer, Servier, and Sanofi. A.A. does not have any conflicts.
Databáze: MEDLINE